ViewRay’s MRIdian Linac Selected as MR-Guided Radiotherapy System in Danish Tender
Top Cancer Centers to Bring Benefits of MR-Guided Soft-tissue Visualization and
November 3, 2017
Adaptive Treatment Delivery to Copenhagen
CLEVELAND, November 3, 2017 – ViewRay, Inc. (Nasdaq: VRAY) announced today that the company’s MRIdian® Linac has been selected for installation
at Rigshospitalet and Herlev Hospitals in Denmark, as part of a competitive bid and comprehensive technology review. As part of the tender award the
regional health system will initially purchase two MRIdian Linac systems.
MRIdian enables a fundamental change from conventional radiotherapy by using diagnostic-quality MR imaging and enabling daily on-table treatment plan adaptation.
MRIdian also uniquely allows for continuous MR imaging to automatically control beam delivery to account for subtle anatomical changes that may occur
during treatment. Combined, these advancements allow clinicians to tailor the dose more closely to the targeted tumor, potentially mitigating incidental
radiation exposure to surrounding healthy tissue and organs.
“Radiation oncology departments are recognizing the value of MR-guidance and its ability to improve the way treatment is visualized, planned and delivered,”
said Chris Raanes, president and CEO of ViewRay. “This purchase illustrates the shift that’s taking place in image-guided radiation therapy and its
impact on clinical practice.”
The purchase of two MRIdian Linac systems for Rigshospitalet and Herlev Hospitals was part of a collaborative bid with Varian Medical Systems, under which
additional Varian treatment machines were also purchased.
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition
MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems
used in diagnostic radiology, MRIdian’s high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion,
and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation
beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements.
Such statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking
statements, include those with respect to the mitigation of radiation exposure to healthy tissue and organs, improvements to treatments, and shifts
in image guided radiation therapy. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements.
Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product
development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay
operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation
to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements,
except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set
forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
Vice President, Marketing
Phone: +1 408-242-2994
# # #